CONSOLIDATED COMPANY RESULTS For 2013, Core Laboratories posted  all-time records for revenue, operating  profit, operating margins, net income,  and free cash flow.  Led by increases in international activities, revenues increased 9% to  $1,073,500,000, and operating profit  grew 12% to $333,400,000, yielding  operating margins of 31%. Year-over- year incremental operating margins  were almost 40%, indicating Core’s  high operating efficiencies, leverage,  and scalability. Net income increased  12% to $242,800,000, and EPS  increased 16% to $5.28. At year’s end, Core’s market capitaliza- tion exceeded $8.5 billion, after touch- ing $9 billion months earlier. The Company  went public in 1995 with a market capi- talization of $120,000,000.  Driving this significant increase in share- holder value is the Company’s focus on  generating maximum amounts of free  cash flow, Core’s first financial tenet.  By selecting projects that generate  high returns on our invested capital,  the Company’s second financial tenet,  Core generates industry-leading rates of  free cash. Core’s FCF in 2013 reached  an all-time high of $262,700,000 after  fully funding the Company’s capital  expenditure program of approximately  $35,400,000. In keeping with Core’s third financial  tenet, the Company continued to return  excess capital back to its shareholders  in 2013 via regular dividends and share  13 12 11 10 09 1,200 1,000 800 600 400 200 0 13 12 11 10 09 350 300 250 200 150 100 50 0 35 30 25 20 15 10 5 0 12 13 11 10 09 6 5 4 3 2 1 0 12 13 11 10 09 Earnings per Diluted Share ($) Operating Margins (%) Operating Profit  Revenues  ($ in millions) ($ in millions) 250 200 150 100 50 0 12 13 11 10 09 300 250 200 150 100 50 0 12 13 11 10 09 Free Cash Flow from Operations Net Income  ($ in millions) ($ in millions)